| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
76,485 |
22,735 |
$3.18M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12,482 |
8,544 |
$897K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
19,857 |
11,568 |
$716K |
| 87634 |
|
19,841 |
11,550 |
$595K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
12,508 |
8,539 |
$252K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12,313 |
6,930 |
$220K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
7,683 |
5,249 |
$148K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
948 |
604 |
$80K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
398 |
381 |
$58K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
411 |
393 |
$8K |
| 87486 |
|
411 |
395 |
$6K |
| 87581 |
|
413 |
396 |
$6K |